CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies

News & Events

CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies, to support the development of innovative therapies for acute liver failure Montréal – Québec – July 7 – CQDM is proud to announce an investment of $260,100 in Morphocell Technologies, a Montréal- based early-stage regenerative medicine company focused on the development of stem cell-derived engineered liver tissue to treat liver disease. … Read More

CQDM invests $500,000 in Giiant Pharma, a Quebec-based pharmaceutical company with strong potential in gastroenterology

News & Events

Montreal – June 30th 2021 – CQDM is proud to invest in Giiant Pharma’s seed financing round, joining co-leads Amplitude Ventures and Genesys Capital, along with Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, AQC Capital, Anges Québec, and other angel investor. This financing will enable Giiant Pharma to become a leader in targeted drug delivery technologies to … Read More

CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University

News & Events

CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University to develop new treatments for Amyotrophic Lateral Sclerosis (ALS) MONTREAL, June 21, 2021 – On this Global Amyotrophic Lateral Sclerosis (ALS) Awareness Day, CQDM is proud to announce a new $1.7M international collaboration between McGill University, Raya Therapeutic (Montreal – Quebec) and Eikonizo Therapeutics (Cambridge – … Read More

CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet

Funded Projects, News & Events

CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet to develop new chemistry to facilitate drug development and manufacturing MONTREAL, June 2nd, 2021 – CQDM is proud to announce a partnership with 3 major pharmaceutical companies, Amgen Canada, Merck Canada, Servier Canada and the Canadian Glycomics Network (GlycoNet) as part of a $1,251,900 funding project. … Read More

Accélérer le passage de l’idée au marché – Dépôt du mémoire des RSRI

News & Events

Accélérer le passage de l’idée au marché – Dépôt du mémoire des RSRI dans le cadre des consultations publiques sur la Stratégie québécoise de la recherche et de l’innovation 2022. (Québec, le 31 mai 2021) – Les regroupements sectoriels de recherche industrielle (RSRI) ont déposé leurs propositions pour stimuler l’innovation dans le cadre des consultations publiques sur la Stratégie québécoise … Read More

CQDM, MEDTEQ+ and Montréal InVivo partner with IVADO to promote digital health innovation

News & Events

Montréal, May 11, 2021 – The Institute for Data Valorization (IVADO) is pleased to announce the signing of network partnerships with the Consortium de recherche biopharmaceutique (CQDM, biopharmaceutical research consortium), the Industrial Consortium for Research and Innovation in Medical Technologies (MEDTEQ+) and Montréal InVivo, the life sciences and health technologies (LSHT) cluster of Greater Montréal. All three are involved in … Read More

CQDM appoints Brian Underdown as the Chair of its Scientific Advisory Board (SAB) and nominates 3 new SAB members

News & Events

MONTREAL, April 28, 2021 — The chairman of the Board of Directors of CQDM, Richard Fajzel, and Diane Gosselin, President and CEO, are very pleased to announce the appointment of Brian Underdown as the new chairman on its Scientific Advisory Board (SAB). Also, David Bouffard, Christine Brideau and Benjamin Haibe-Kains are joining this strategic committee, whose primary mandate is to … Read More

We are hiring! Director – Business development – Apply now!

Job offers

Open position available: Director – Business development ABOUT CQDM  Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective … Read More

We are hiring! Project managers – Apply now!

Job offers

Open positions available: Project managers ABOUT CQDM  Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective drugs. We … Read More

48Hour Discovery and Merck initiate drug discovery project – Project funded through CQDM Quantum Leap program

News & Events

Montréal – Québec –  March 15, 2021 – 48Hour Discovery(48HD) and CQDM are proud to announced that the company has been awarded $800,000 for peptide drug discovery using its patented drug discovery platform. The two-year project is funded through the CQDM Quantum Leap program, which supports exploration of innovative technologies, tools, and platforms that accelerate or facilitate drug discovery and … Read More